Keryx Biopharmaceuticals said on Tuesday that Greg Madison was appointed to the company´s board of directors.
Madison joined Keryx in 2014 and serves as the company´s president and chief operating officer. He will transition into the role of CEO by the end of May.
"We believe that Greg will drive significant value for our company as he takes over the helm in the coming weeks as CEO,” Michael Tarnok, chairman of Keryx´s board of directors, said. “As he continues to execute our vision of building a world-class specialty pharmaceutical company, with a focus on delivering innovative therapeutics to patients with renal disease, it is a pleasure to welcome Greg to the board of Keryx."
Madison has more than 20 years of experience in the U.S. pharmaceuticals industry. Prior to Keryx, he served as executive vice president and chief commercial officer of AMAG Pharmaceuticals, where he led the team to considerable growth in net revenues.
Madison also spent 12 years at Genzyme/Sanofi developing extensive commercial and general management skills. He proceeded into leadership roles and served as vice president and general manager of the renal division, where he led a global organization with three marketed products with combined revenues of more than $1 billion.